You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Highly Multiplexed Analysis of Solid Tumors and Liquid Tissues by Cyclic Immunofluorescence

    SBC: RareCyte, Inc.            Topic: 102

    PROJECT SUMMARY The long term goal of this proposal is to developvalidate and market robustcost effective technologies for highly multiplexed imaging of cells in liquid and solid biopsies at sub cellular resolution as a means to diagnose diseaseidentify patients likely to benefit from specific anti cancer drugsand investigate mechanisms of action of cytoxictargeted and immuno oncology drugsThis wi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation

    SBC: CHIMEROCYTE INC            Topic: 102

    ABST RACT Patients with acute blood malignancies who undergo allogeneic hematopoietic stem cell transplantationHSCTare monitored for minimal residual diseaseMRDas predictive of relapseIncreasing mixed chimerismreemerging recipient cellscorrelates with reappearance of underlying disease by association with MRDGenetic and immunophenotypic heterogeneity of these malignancies often prevents establishi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Spirulina-based oral malaria vaccine

    SBC: Lumen Bioscience, Inc.            Topic: NIAID

    ABSTRACT Vaccination represents the single most effective and cost effective medical intervention devised to datesaving lives and reducing morbidity and disability for billions of humansDespite the early success of the oral polio vaccinemost vaccines are delivered parenterallyand as such are associated with painnon compliancebiohazardous medical waste and strict requirements for expensive producti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Robust Predictor of Colon Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 102

    Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations

    SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC            Topic: NIA

    Project Summary and Abstract Falls are the leading cause of death due to injuryThis simple motion is so common thatof community dwelling older adultsandof long term care facilities will experience a fall in the coming yearThe risk of falling substantially increases for those having Alzheimer s disease and related dementiasand those with Parkinson s diseaseThe financial burden is significant with f ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government